Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Vervloet, Marc G ^a   Van Zuilen, Arjan D ^b   Heijboer, Annemieke C ^a   Ter Wee, Piet M ^a   Bots, Michiel L ^b   Blankestijn, Peter J ^b   Wetzels, Jack F M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; CKD; FGF23; Phosphate; Proteinuria; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PLASMA; PROTEINURIA; SMOKING; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; MIDDLE AGED; NETHERLANDS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; COHORT STUDIES; COMORBIDITY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84859931666     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-20     Document Type: Article

References (42)

1. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
2. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, BMJ 2006 332 1426 10.1136/bmj.38814.566019.2F 16714328 (Pubitemid 44365322)
3. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M, N Engl J Med 2008 359 584 592 10.1056/NEJMoa0706130 18687639
4. FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, J Am Soc Nephrol 2011 22 1913 1922 10.1681/ASN.2010121224 21903574
5. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moyses RM, Clin J Am Soc Nephrol 2011 6 241 247 10.2215/CJN.04250510 20966122
6. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Ix JH, Shlipak MG, Wassel CL, Whooley MA, Nephrol Dial Transplant 2010 25 993 997 10.1093/ndt/gfp699 20037168
7. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C, Kidney Int 2010 78 679 685 10.1038/ki.2010.194 20613714
8. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Mirza MA, Larsson A, Lind L, Larsson TE, Atherosclerosis 2009 205 385 390 10.1016/j.atherosclerosis.2009.01.001 19181315
9. FGF23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, guillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John, Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe O, Kuro O, Kusek JW, Keane MG, Wolf M, J Clin Invest 2011 121 4393 4408 10.1172/JCI46122 21985788
10. Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, Van Buren M, Ten Dam MA, Kaasjager KA, Van De V, Vleming LJ, Ligtenberg G, Ligtenberg G, J Nephrol 2005 18 30 34 15772920 (Pubitemid 40723750)
11. Determination of fibroblast growth factor 23. Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM, Blankenstein MA, Ann Clin Biochem 2009 46 338 340 10.1258/acb.2009.009066 19564163
12. The MDRD formula and validation. Twomey PJ, Reynolds TM, QJM 2006 99 804 805 10.1093/qjmed/hcl108 17041249 (Pubitemid 44688417)
13. Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Fukumoto S, Intern Med 2008 47 337 343 10.2169/internalmedicine.47.0730 18310961 (Pubitemid 351663682)
14. Phosphate and FGF-23. Juppner H, Kidney Int Suppl 2011 79 24 S27
15. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM, Clin J Am Soc Nephrol 2011 6 383 389 10.2215/CJN.04730510 21030580
16. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T, Am J Physiol Renal Physiol 2010 299 882 F889 10.1152/ajprenal.00360.2010 20685823
17. Effects of nicotine administration and nicotine cessation on bone histomorphometry and bone biomarkers in Sprague-Dawley male rats. Hapidin H, Othman F, Soelaiman IN, Shuid AN, Mohamed N, Calcif Tissue Int 2011 88 41 47 10.1007/s00223-010-9426-4 20953592
18. Impact of smoking on bone mineral density and bone metabolism in elderly men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Tamaki J, Iki M, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N, Osteoporos Int 2011 22 133 141 10.1007/s00198-010-1238-x 20383631
19. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T, Nature 2006 444 770 774 10.1038/nature05315 17086194 (Pubitemid 44949607)
20. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. de Borst MH, Vervloet MG, ter Wee PM, Navis G, J Am Soc Nephrol 2011 22 1603 1609 10.1681/ASN.2010121251 21852584
21. Adverse effects of nicotine and immunosuppression on proximal tubular epithelial cell viability, tissue repair and oxidative stress gene expression. Khanna AK, Xu J, Baquet C, Mehra MR, J Heart Lung Transplant 2009 28 612 620 10.1016/j.healun.2009.03.003 19481023
22. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Marsell R, Mirza MA, Mallmin H, Karlsson M, Mellstrom D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE, Osteoporos Int 2009 20 1167 1173 10.1007/s00198-008-0780-2 18974917
23. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, JAMA 2011 305 2432 2439 10.1001/jama.2011.826 21673295
24. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Dalal M, Sun K, Cappola AR, Ferrucci L, Crasto C, Fried LP, Semba RD, Eur J Endocrinol 2011 165 797 803 10.1530/EJE-11-0577 21873490
25. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A, J Ren Nutr 2011 21 295 302 10.1053/j.jrn.2010.07.002 20817560
26. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD, J Am Soc Nephrol 2006 17 1305 1315 10.1681/ASN.2005111185 16597685 (Pubitemid 43673410)
27. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. D'Amico G, Ferrario F, Rastaldi MP, Am J Kidney Dis 1995 26 124 132 10.1016/0272-6386(95)90165-5 7611242
28. Pathophysiology of progressive nephropathies. Remuzzi G, Bertani T, N Engl J Med 1998 339 1448 1456 10.1056/NEJM199811123392007 9811921 (Pubitemid 28516069)
29. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study. Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Lysiak-Szydlowska W, Wozniak M, Rutkowski B, Acta Biochim Pol 2010 57 119 123 20309434
30. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P, J Am Soc Nephrol 2007 18 2600 2608 10.1681/ASN.2006080936 17656479 (Pubitemid 47378877)
31. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Perwad F, Zhang MY, Tenenhouse HS, Portale AA, Am J Physiol Renal Physiol 2007 293 1577 F1583 10.1152/ajprenal.00463.2006 17699549 (Pubitemid 350085994)
32. Smoking and hypertension as predictors of cardiovascular risk in population studies. Kannel WB, Higgins M, J Hypertens Suppl 1990 8 3 S8 2081997
33. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? de Zeeuw D, Kidney Int Suppl 2004 33 2 S6
34. Phosphate levels and cardiovascular disease in the general population. Foley RN, Clin J Am Soc Nephrol 2009 4 1136 1139 10.2215/CJN.01660309 19423568
35. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Hruska K, Mathew S, Lund R, Fang Y, Sugatani T, Kidney Int Suppl 2011 79 9 13
36. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Pijls LT, de Vries H, Donker AJ, van Eijk JT, Nephrol Dial Transplant 1999 14 1445 1453 10.1093/ndt/14.6.1445 10383006 (Pubitemid 29241736)
37. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H, J Clin Endocrinol Metab 2010 95 578 585 10.1210/jc.2009-1603 19965919
38. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Price CP, Newall RG, Boyd JC, Clin Chem 2005 51 1577 1586 10.1373/clinchem.2005.049742 16020501 (Pubitemid 41233090)
39. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A, Nephrol Dial Transplant 2011 26 2567 2571 10.1093/ndt/gfr144 21436379
40. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T, Ther Apher Dial 2005 9 336 339 10.1111/j.1744-9987.2005.00293.x 16076378 (Pubitemid 41800805)
41. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Oliveira RB, Cancela AL, Graciolli FG, dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM, Clin J Am Soc Nephrol 2010 5 286 291 10.2215/CJN.05420709 19965540
42. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD, Clin J Am Soc Nephrol 2010 5 110 116 10.2215/CJN.03630509 19965548